Overview
On A Limb: How Can We Better Optimize PAD Care?
The Expert Circle
Click the "View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity
Are your patients with PAD post-revascularization “on a limb”? Find out as Marc Bonaca, MD, MPH covers the latest guideline recommendations and clinical trial data related to managing patients with PAD post-revascularization. This expert perspective provides clinicians with practical insights to apply to their practice.
This activity is intended for clinical cardiologists, vascular surgeons, interventional cardiologists, and primary care physicians.
The purpose of this activity is to provide learners with an engaging, practical presentation to help them optimize anticoagulant therapy in their patients with PAD post-revascularization. Learners post-activity will be better able to interpret the latest data on DOACs in PAD post-revascularization as well as optimize anticoagulant therapy for these patients.
Upon completion of this activity, participants will be able to:
• Interpret the latest data on DOACs in PAD post-revascularization
• Optimize anticoagulant therapy for patients with PAD post-revascularization
• Interpret the latest data on DOACs in PAD post-revascularization
• Optimize anticoagulant therapy for patients with PAD post-revascularization
This activity is supported by an educational grant from Janssen Scientific Affairs, LLC.
This activity was part of a serial learning curriculum. This functionality is no longer available due to activity expiration.
Marc Bonaca, MD, MPH
Executive Director, CPC
Professor of Medicine, Cardiology & Vascular Medicine
Director of Vascular Research, University of Colorado SOM
Aurora, CO
Executive Director, CPC
Professor of Medicine, Cardiology & Vascular Medicine
Director of Vascular Research, University of Colorado SOM
Aurora, CO
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.
The following financial relationships have been provided:
Marc Bonaca, MD, MPH
Consultant (through CPC, an Academic Research Organization): Amgen, AstraZeneca, Audentes, Bayer, Cook, Janssen, Lexicon, Merck, NovoNordisk, PhaseBio, Regeneron, Sanifit, Wraser
Grants (through CPC, an Academic Research Organization): Amgen, ARCA BioPharma, AstraZeneca, Bayer, Janssen, Lexicon, NovoNordisk
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Rivaroxaban for patients with PAD post-revascularization
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
This activity will take approximately 30 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 66% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of .50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
